BlogCancer

New Study: PSMA-PET Imaging Helps Nearly Half of Men Avoid Unnecessary Prostate Biopsy

One of the biggest challenges in prostate cancer care has been overdiagnosis: finding cancers that would never cause harm, which leads to unnecessary biopsies, anxiety and sometimes treatment. A trial presented at the European Association of Urology Congress in London in March 2026, and published in The Lancet Oncology in June, offers a step forward.12

What is PSMA-PET?

PSMA-PET/CT (prostate-specific membrane antigen positron emission tomography) uses a radioactive tracer to show prostate cancer cells. PSMA is a protein found in large amounts on the surface of prostate cancer cells, which makes them visible on the scan. PSMA-PET is already used for staging prostate cancer. PRIMARY2 tested it earlier, in men whose MRI showed no clearly suspicious lesion.

What did the PRIMARY2 trial find?

PRIMARY2 was a phase 3 randomized trial at seven Australian hospitals. It enrolled 660 men who had never had a biopsy, with a PSA of 20 or less, and an MRI that was equivocal (PI-RADS 3) or not suspicious (PI-RADS 2) but with high clinical risk. Half were assigned to a standard systematic biopsy. The other half had a PSMA-PET scan, and only those with a positive scan had a targeted biopsy.1

660 menrandomized at seven Australian hospitals
49%of the PSMA-PET group avoided a biopsy
12 vs 16%clinically significant cancer found, PSMA-PET vs systematic biopsy (non-inferior)

Figures as reported in the published trial; see source 1.

  • 163 of 331 men in the PSMA-PET group (49%) avoided biopsy.1
  • Clinically significant cancer was found in 12% of the PSMA-PET group and 16% of the biopsy group, a difference within the trial’s pre-set margin for non-inferiority.1
  • Low-risk cancer that needed no treatment was found in 14% of the PSMA-PET group, against 32% of the biopsy group.2
  • Among men who did have a biopsy, pain, blood in the urine and blood in the semen were reported at similar rates in both groups.1

Why this matters for patients

Prostate biopsy is routine, but it is still an invasive procedure, with possible discomfort, bleeding and a small risk of infection. Finding a low-risk cancer can also start a cascade of anxiety, further tests and monitoring. A test that reliably separates men who need a biopsy from those who do not would be a meaningful advance.

What it does not change yet

The authors call for more research, including cost analyses and studies with other PSMA tracers, before this approach is put into routine practice.1 The AUA/SUO early-detection guideline (2023, amended 2026) does not yet include PSMA-PET in its recommendations for deciding on a first biopsy; it relies on PSA, MRI, risk calculators and biomarkers.3 For now, the standard pathway after a raised PSA is a repeat PSA, then MRI and, where needed, a targeted biopsy.

What about PSA screening?

PRIMARY2 does not change whether to be screened; it may improve what happens after a PSA result raises concern. The U.S. Preventive Services Task Force (2018) calls screening an individual decision for men aged 55 to 69 and recommends against it at 70 and older.4 The AUA/SUO guideline recommends offering screening every 2 to 4 years from 50 to 69, a baseline PSA between 45 and 50, and screening from 40 to 45 for men at higher risk: Black men, men with germline mutations, and men with a strong family history.3 Both start with a conversation. Our PSA screening guide sets out the two side by side.

At Urological Consultants of Florida, Dr. Robbins offers PSA screening after that conversation, MRI-ultrasound fusion targeted prostate biopsy, and individual cancer risk assessment.

Sources

  1. Buteau JP, Moon D, Fahey MT, et al.; PRIMARY2 Trial Investigators. Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial. Lancet Oncol 2026;27(7):839-848; published online June 10, 2026; accessed October 2026.
  2. European Association of Urology. Scan that makes prostate cancer cells glow could cut need for biopsies. EAU26 Congress press release, London, March 13, 2026; accessed October 2026.
  3. Wei JT, Barocas D, Carlsson S, et al.; amendment panel Lin DW, et al. Early Detection of Prostate Cancer: AUA/SUO Guideline (2023, amended 2026). American Urological Association / Society of Urologic Oncology; amendment approved February 2026 (J Urol 2026;215(5):491-501, PMID 41744286); accessed October 2026.
  4. U.S. Preventive Services Task Force. Prostate Cancer: Screening. Final recommendation, May 8, 2018 (JAMA 2018;319(18):1901-1913, PMID 29801017). The page notes an update in progress; accessed October 2026.

Contact Us

We’re here to help. Schedule your visit or ask a question today.

No question is too small — and nothing you share here surprises us. Reach out however feels easiest.

  • Call(305) 672-4222
  • Visit12411 Biscayne Boulevard
    North Miami, FL 33181
  • HoursMonday–Friday, 9:00 am – 5:00 pm

Your message goes to Dr. Robbins’ own team — you’ll hear back within one business day.

Get More Information

By sending this form you agree to our Terms of Service, Privacy Policy, and Notice of Privacy Practices.

Your message is confidential. We’ll respond within one business day.

We’re Here When You Need Us

Our Office

Visit us in North Miami, or call to book your appointment.

North Miami

  • Address12411 Biscayne Boulevard
    North Miami, FL 33181
  • Phone(305) 672-4222
  • Fax(305) 944-3624
Office hours
Monday – Friday9:00 am – 5:00 pm
Saturday – SundayClosed

Associations

Proud Members Of

American Board of Urology American College of Surgeons NYU Medical Center Miller School of Medicine Brandeis University Greenlight